深圳市AI+药械研发公共服务平台正式启动

Core Insights - The 27th China International High-tech Achievements Fair concluded with a focus on the development of innovative pharmaceuticals in Shenzhen, emphasizing the theme "AI Empowerment, Moving Forward" [1][3] Group 1: Event Overview - The forum was guided by the Shenzhen Development and Reform Commission and the Shenzhen Science and Technology Innovation Bureau, hosted by Shenzhen Polytechnic University, featuring top academicians and industry leaders [3] - Key activities included policy interpretation, platform launches, achievement announcements, project signings, and high-level dialogues [3] Group 2: Policy and Infrastructure Development - Shenzhen is actively promoting high-quality development in the biopharmaceutical industry, establishing a city-level medical device office, implementing supportive policies, and creating a new medical academy mechanism [3] - The city has set up over 10 billion yuan industry funds and is focusing on AI drug development among other new tracks [3] Group 3: AI and Pharmaceutical Research Initiatives - The Shenzhen AI + Pharmaceutical Research Public Service Platform was officially launched, integrating multiple AI-driven research platforms to enhance drug development [5] - The forum also introduced the "AI for Science Innovation Application Competition" to foster innovation teams in the biopharmaceutical sector [5] Group 4: Research Collaborations and Project Signings - Shenzhen Polytechnic University signed eight major projects with various enterprises and institutions to enhance research collaboration and talent cultivation [6] - These initiatives aim to strengthen the foundation for high-quality development in the biopharmaceutical industry [6] Group 5: Industry Achievements and Future Goals - The forum highlighted 10 innovative pharmaceutical achievements expected by 2025, covering areas such as AI drug development, cell therapy, and targeted cancer drugs [5] - From 2015 to 2024, China has developed a total of 3,575 innovative drugs, surpassing the United States, with Shenzhen positioned as a key base in the biopharmaceutical industry aiming for an annual output value of 200 billion yuan [8]